summary: Human mesenchymal stem cells (hMSCs) are being considered for clinical trials of multiple sclerosis (MS). The authors studied the effect of these stem cells in a specific subgroup of immune system cells. They found that soluble products from hMSCs inhibited the responses of some immune cells that are involved in the inflammatory process. They concluded that further preclinical work and immune-monitoring may define hMSC effects on disease under variable conditions.

authors: Darlington PJ, Boivin MN, Renoux C, François M, Galipeau J, Freedman MS, Atkins HL, Cohen JA, Solchaga L, Bar-Or A.

source: Ann Neurol. 2010 Jul 26.

weblink: click here

category: Clinical Trials and Therapeutics

related research news: click here

glossary: